Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.
The purpose of this study was to collect blood samples of hypertensive patients, in order to clarify the correlation between serum miR-455-5p level and cardiac function. Generally, by using q-PCR assay, miR-455-5p level of each participants will be collected. Besides, SBP, DBP, LVPWd, LVIDd, IVSTd was detected by echocardiography and EF, FS, LVMi, RWT level was further calculated by LVIDd, LVPWd and IVSTd. Finally, the correlation of miR-455-5p level of HHD patients and LVPWd, LVIDd, IVSTd, EF, FS, LVMi, RWT, SBP, DBP was analysed.
Study Type
OBSERVATIONAL
Enrollment
46
the University of Hongkong-Shenzhen Hospital
Shenzhen, Guangdong, China
Measurement of serum miR-455-5p level
concentration of microRNA-455-5p in 100ml serum was determined by Elisa assay.
Time frame: the miR-455-5p level is collected at week 0, 6, 12 and 24.
Measurement of LVPWd and LVPWs
left ventricular posterior wall thickness in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
Time frame: the LVPWd and LVPWs are collected at week 0, 6, 12 and 24.
Measurement of LVIDd and LVIDs
left ventricular internal diameter in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
Time frame: the LVIDd and LVIDs are collected at week 0, 6, 12 and 24.
Measurement of IVSTd and IVSTs
interventricular septum in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
Time frame: the IVSTd and IVSTs are collected at week 0, 6, 12 and 24.
Calculation of LVMi
left ventricular mass index was calculated based on the formula: LVMi=LVM/BSA; For LVM, LVM(g)=0.8\*1.04\*\[(IVSTd+LVPWd+LVIDd)\^3-LVIDd\^3\]+0.6; For BSA, BSA=\[Body height (cm)\*Body weight (kg)/3600\]\^0.5； Diagnosis of LVH: LVMi(Male)\>115g/m2；LVMi(Female)\>95g/m2
Time frame: the LVMi is calculated at week 0, 6, 12 and 24.
Measurement of LVEF
left ventricular ejection fraction are measured and recorded by echocardiography and its affiliated software. Generally, LVEF is range from 50% to 70% is regarded as normal. If LVEF less than 50%, the patient is suspected to suffered cardiac systolic dysfunction.
Time frame: the EF is calculated at week 0, 6, 12 and 24.
Measurement of FS
Fractional shortening are measured and recorded by echocardiography and its affiliated software. Generally, FS is range from 25% to 45% is regarded as normal. If FS less than 25%, the patient is suspected to suffered cardiac systolic dysfunction.
Time frame: the FS is calculated at week 0, 6, 12 and 24.
SBP
systolic blood pressure was measured by sphygmomanometer. For patients whose SBP is higher than 140mmHg, the patients is regarded as hypertension.
Time frame: the SBP is collected at week 0, 6, 12 and 24.
DBP
diastolic blood pressure was measured by sphygmomanometer. For patients whose DBP is higher than 90mmHg, the patients is regarded as hypertension.
Time frame: the DBP is collected at week 0, 6, 12 and 24.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.